GEN Exclusives

More »

GEN News Highlights

More »
Sep 10, 2007

RXi Pharmaceuticals Licenses RNA Chemistry Technologies from TriLink Biotechnologies

  • RXi Pharmaceuticals exclusively licensed three RNAi chemistry technologies from TriLink Biotechnologies. The agreement includes rights to sublicense a patented RNA linker technology, a patent application on novel RNAi compositions, and an undisclosed chemistry approach that has potential applications in improving existing RNAi compounds, according to the companies.

    “This chemistry technology adds components to our expanding RNAi toolbox and can be integrated with our existing technology portfolio to create advanced RNAi compounds that we call rxRNA™,” comments Tod Woolf, Ph.D., CEO of RXi. “rxRNA is patently distinct from first-generation siRNA and has shown certain potential advantages in terms of potency and other pharmacological properties.”

    Terms of the license agreement include upfront and yearly minimum licensing payments, royalties of 1% or less on sales of resulting therapeutic products, and fees based on the achievement of certain clinical milestones.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?